With an increase in breast cancer cases worldwide and rising investments in the research and development projects for breast cancer treatment, the Global breast cancer therapeutics market is expected to grow from $18.2 Bn in 2022 to $48.04 Bn in 2030 with a CAGR of 12.9% for the year 2022-2030. The market is segmented by therapy, by cancer type, and by distribution channel. To get a detailed report, contact us at - info@insights10.com

1. GLOBAL
THERAPEUTICS MARKET
ANALYSIS, 2022-2030
BREAST
CANCER

2. CONTENTS
Global Breast Cancer Therapeutics Market Analysis, 2022-2030
1. Overview
2. Prevalence of Breast Cancer in the World
3. Types of Breast Cancer
4. Drugs Approved for Breast Cancer
5. Market Size and Key Findings
6. Regional Analysis
7. Market Dynamics
8. Competitive Landscape
9. Healthcare Policy and Regulatory Landscape
10. Reimbursement Scenario
11. Latest Trends and Innovations
12. Conclusion
03
04
08
12
15
16
20
21
22
23
24
25

3. Overview
The Global Breast Cancer Therapeutics Market is projected to grow from $18.2 Bn in 2022 to $48.0 Bn by 2030,
registering a CAGR of 12.9% during the forecast period of 2022 - 2030.
Breast cancer is the second most common cancer in women worldwide, after skin cancer. The global breast
cancer therapeutics market is a rapidly growing market and is expected to continue to grow in the coming years.
The market for breast cancer therapeutics is driven by a number of factors, including the increasing prevalence of
breast cancer, the development of new and innovative drugs, and the growing demand for personalized medi-
cine. The market is also benefiting from several initiatives and campaigns to raise awareness about breast cancer
and the importance of early detection and treatment.
Some of the key players in the breast cancer therapeutics market include AstraZeneca, Roche, Pfizer, Novartis,
and Eli Lilly. These companies are investing heavily in research and development to develop new treatments and
improve existing ones. They are also working to improve patient access to breast cancer treatments by expanding
their distribution networks and working with healthcare providers to improve diagnosis and treatment.
The breast cancer therapeutics market is segmented by type of therapy, including chemotherapy, targeted
therapy, hormonal therapy, and others. The market is also segmented by types, distribution channels and regions.
Overall, the global breast cancer therapeutics market is expected to continue to grow at a rapid pace in the
coming years, driven by increasing demand for effective treatments and ongoing investment in research and
development.
Global Breast Cancer Therapeutics Market (in $ Bn)
Matket is forecast to grow at a CAGR of 12.9%
18.2
2022
20.5
2023F
23.2
2024F
26.2
2025F
29.8
2026F
33.4
2027F
37.7
2028F
42.6
2029F
48.0
2023F
03
Global Breast Cancer Therapeutics Market Analysis, 2022-2030

4. 04
With 1 in 8 cancer diagnoses worldwide, breast cancer is the most frequently diagnosed cancer kind. Each year,
there are more than 2.3 Mn new instances of breast cancer in the world, and there were also approximately
685,000 deaths from this illness, with significant regional variances between different nations and global areas.
Breast cancer is the primary or secondary cause of mortality for women from cancer in 95% of the world's
nations. However, there are significant disparities in breast cancer survival between and within nations. Nearly
80% of breast and cervical cancer fatalities take place in low- and middle-income nations.
The most significant risk factor is age, and the oldest females have the highest age-specific incidence rates. Less
than one in five women with breast cancer is diagnosed before the age of 50 in the UK, while more than one-third
of cases affect women beyond the age of 70. In contrast, more than half of breast cancer cases in women under
50 years old occur in less developed nations.
These disparities in breast cancer incidence and survival are likely due to a number of factors, including access to
healthcare, screening programs, and awareness of the signs and symptoms of breast cancer. In many low- and
middle-income countries, women do not have regular access to healthcare, and screening programs for breast
cancer are not widely available. As a result, breast cancer is often diagnosed at a later stage, when it is more
difficult to treat and less likely to be cured.
What is the Prevalence of
Breast Cancer in the World?
Global Breast Cancer Therapeutics Market Analysis, 2022-2030

5. All sites
Breast
Oral cavity pharynx
Tongue
Mouth
Pharynx
Other oral cavity
Digestive system
Esophagus
Stomach
Small intestine
Colon rectum
Colon
Rectum
Anus, anal canal, anorectum
Liver intrahepatic bile duct
Gallbladder other biliary
Pancreas
Other digestive organs
Respiratory system
Larynx
Lung bronchus
Other respiratory organs
Bones joints
Soft tissue (including heart)
Skin (excluding basal squamous)
Melanoma of the skin
Other nonepithelial skin
Genital system
1,958,310
300,590
54,540
18,040
14,820
20,070
1610
348,840
21,560
26,500
12,070
153,020
106,970
46,050
9760
41,210
12,220
64,050
8450
256,290
12,380
238,340
5570
3970
13,400
104,930
97,610
7320
414,350
1,010,310
2800
39,290
13,180
8680
16,340
1090
194,980
17,030
15,930
6580
81,860
54,420
27,440
3180
27,980
5750
33,130
3540
131,150
9900
117,550
3700
2160
7400
62,810
58,120
4690
299,540
948,000
297,790
15,250
4860
6140
3730
520
153,860
4530
10,570
5490
71,160
52,550
18,610
6580
13,230
6470
30,920
4910
125,140
2480
120,790
1870
1810
6000
42,120
39,490
2630
114,810
609,820
43,700
11,580
2940
3090
4140
1410
172,010
16,120
11,130
2070
52,550
0
0
1870
29,380
4510
50,550
3830
132,330
3820
127,070
1440
2140
5140
12,470
7990
4480
69,660
322,080
530
8140
1950
1870
3260
1060
99,350
12,920
6690
1170
28,470
0
0
860
19,000
1900
26,620
1720
71,170
3070
67,160
940
1200
2720
8480
5420
3060
35,640
287,740
43,170
3440
990
1220
880
350
72,660
3200
4440
900
24,080
0
0
1010
10,380
2610
23,930
2110
61,160
750
59,910
500
940
2420
3990
2570
1420
34,020
Estimated new cancer cases and deaths by sex, US, 2023
Cancer Site
Estimated New Cases Estimated Deaths
Both Sexes Male Female Both Sexes Male Female
05
Global Breast Cancer Therapeutics Market Analysis, 2022-2030

6. Uterine cervix
Uterine corpus
Ovary
Vulva
Vagina other female genital
Prostate
Testis
Penis other male genital
Urinary system
Urinary bladder
Kidney renal pelvis
Ureter other urinary organs
Eye orbit
Brain other nervous system
Endocrine system
Thyroid
Other endocrine
Lymphoma
Hodgkin lymphoma
Non‐Hodgkin lymphoma
Myeloma
Leukemia
Acute lymphocytic leukemia
Chronic lymphocytic leukemia
Acute myeloid leukemia
Chronic myeloid leukemia
Other leukemia
Other unspecified primary sites
13,960
66,200
19,710
6470
8470
288,300
9190
2050
168,560
82,290
81,800
4470
3490
24,810
47,230
43,720
3510
89,380
8830
80,550
35,730
59,610
6540
18,740
20,380
8930
5020
32,590
0
0
0
0
0
288,300
9190
2050
117,590
62,420
52,360
2810
1900
14,280
14,340
12,540
1800
49,730
4850
44,880
19,860
35,670
3660
12,130
11,410
5190
3280
16,810
13,960
66,200
19,710
6470
8470
0
0
0
50,970
19,870
29,440
1660
1590
10,530
32,890
31,180
1710
39,650
3980
35,670
15,870
23,940
2880
6610
8970
3740
1740
15,780
4310
13,030
13,270
1670
1740
34,700
470
470
32,590
16,710
14,890
990
430
18,990
3240
2120
1120
21,080
900
20,180
12,590
23,710
1390
4490
11,310
1310
5210
48,160
0
0
0
0
0
34,700
470
470
22,680
12,160
9920
600
240
11,020
1560
970
590
12,320
540
11,780
7000
13,900
700
2830
6440
780
3150
26,130
4310
13,030
13,270
1670
1740
0
0
0
9910
4550
4970
390
190
7970
1680
1150
530
8760
360
8400
5590
9810
690
1660
4870
530
2060
22,030
Global Breast Cancer Therapeutics Market Analysis, 2022-2030
06

7. Depicts The Most Common Cancers Diagnosed in Men
Women In 2023
Estimated New Cases
Prostate
Lung bronchus
Colon rectum
Urinary bladder
Melanoma of the skin
Kidney renal pelvis
Non-Godgkin lymphoma
Oral cavity pharynx
Leukemia
Pancreas
All sites
Breast
Lung bronchus
Colon rectum
Uterine corpus
Melanoma of the skin
Non-Hodgkin hymphoma
Thyroid
Pancreas
Kidney renal pelvis
Leukemia
All Sites
Males Females
288,300
117,550
81,860
62,420
58,120
52,360
44,880
39,290
35,670
33,130
1,010,310
297,790
120,790
71,160
66,200
39,490
35,670
31,180
30,920
29,440
23,940
948,000
31%
13%
8%
7%
4%
4%
3%
3%
3%
3%
100%
29%
12%
8%
6%
6%
5%
4%
4%
4%
3%
100%
Estimated Deaths
Lung bronchus
Prostate
Colon rectum
Pancreas
Liver intrahepatic bile duct
Leukemia
Esophagus
Urinary bladder
Non-Hodgkin lymphoma
Brain other nervous system
All sites
Lung bronchus
Breast
Colon rectum
Pancreas
Ovary
Uterine corpus
Liver intrahepatic bile duct
Leukemia
Non-Hodgkin lymphoma
Brain other nervous system
All sites
Males Females
67,160
34,700
28,470
26,620
19,000
13,900
12,920
12,160
11,780
11,020
322,080
59,910
43,170
24,080
23,930
13,270
13,030
10,380
9,810
8,400
7,970
287,740
21%
15%
8%
8%
5%
5%
4%
3%
3%
3%
100%
21%
11%
9%
8%
6%
4%
4%
4%
4%
3%
100%
07
Global Breast Cancer Therapeutics Market Analysis, 2022-2030
Nearly half (48%) of all incident instances of cancer in males are for the prostate, lung and bronchus (hereafter lung),
and colorectal cancers (CRCs), with 29% of diagnoses coming from prostate cancer alone.
Breast cancer alone accounts for 31% of all cancer diagnoses in women, whereas lung cancer, CRC, and breast
cancer together account for 52% of all new diagnoses.

8. 08
Global Breast Cancer Therapeutics Market Analysis, 2022-2030
Types of
Breast Cancer?
There are several types of breast cancer, which are characterized based on the specific cells and tissues where the
cancerous growth originates. The most common types of breast cancer are:
Invasive Ductal Carcinoma (IDC)
Ductal Carcinoma in Situ (DCIS)
Invasive Lobular Carcinoma (ILC)
Triple-negative Breast Cancer (TNBC)
Metastatic Breast Cancer
Tubular Breast Cancer
Mucinous Breast Cancer
Inflammatory Breast Cancer (IBC)
Medullary Breast Cancer

9. Ductal Carcinoma in Situ (DCIS):
Distribution of new DCIS type breast cancer cases in the US
BY age group
09
Global Breast Cancer Therapeutics Market Analysis, 2022-2030
DCIS is a non-invasive form of breast cancer that develops in the milk ducts of the breast. It is considered a pre-can-
cerous condition, as the abnormal cells are confined to the ducts and have not spread to nearby tissue.
In the US now, DCIS accounts for 20% to 25% of breast cancer diagnoses. This has increased along with the intro-
duction of screening mammography because a sizable portion of DCIS is initially discovered on screening mam-
mography. DCIS made up fewer than 5% of newly diagnosed breast cancers during the pre-screening mammogra-
phy period.
Treatments available for Ductal Carcinoma in Situ (DCIS):
▪ Breast-conserving surgery (BCS)
▪ Mastectomy
▪ Hormone therapy after breast surgery
Invasive Ductal Carcinoma (IDC):
IDC is the most common type of breast cancer, accounting for approximately 80% of all cases. It begins in the milk
ducts of the breast but then invades the surrounding breast tissue.
Treatment for invasive ductal carcinoma
Invasive ductal carcinoma may be treated with:
▪ Surgery:
▪ Radiation Therapy:
▪ Chemotherapy:
▪ Hormonal Therapy
▪ Targeted Therapy
▪ Immunotherapy
1%
1
0
%
2
8
%
2
7
%
2
1
%
1
1
%
2
%
75-84 Years
64-74 Years
54-64 Years
45-54 Years
34-44 Years
20-34 Years
85 Years older

10. 10
Global Breast Cancer Therapeutics Market Analysis, 2022-2030
Estimated New Invasive Breast Cancer Cases among Women
by Age, US, 2019
Age
40
40-49
50-59
60-69
70-79
79
Numbers
11,870
37,150
61,560
74,820
52,810
30,390
%
4
14
23
28
20
11
Invasive Lobular Carcinoma (ILC):
ILC originates in the lobules of the breast, which produce milk. It is less common than IDC, accounting for about
10-15% of all breast cancers. Treatment options may include surgery, radiation therapy, chemotherapy, and
hormonal therapy.
Inflammatory Breast Cancer (IBC):
IBC is a rare and aggressive form of breast cancer that typically presents as a red, swollen, and warm breast. It
occurs when cancer cells block the lymphatic vessels in the skin of the breast. Treatment for IBC usually involves a
combination of different therapies, including Chemotherapy, Surgery, Radiation therapy, Targeted therapy, and
Hormone therapy.
Triple-negative Breast Cancer (TNBC):
TNBC is a type of breast cancer that tests negative for estrogen receptors, progesterone receptors, and HER2/neu.
This means that the cancer does not respond to hormonal therapy or targeted therapies that are effective for other
types of breast cancer. Treatment options may include surgery, radiation therapy, chemotherapy, and targeted
therapy.
Lobular Carcinoma in Situ (LCIS):
When abnormal cells are discovered in the breast lobules, it is known as lobular carcinoma in situ (LCIS). The breast
tissue around the lobules is not affected by the atypical cells.
Metastatic Breast Cancer:
Stage 4 breast cancer sometimes refers to metastatic breast cancer. Other body parts are now affected by the
malignancy. Usually, the liver, bones, brain, and lungs are included in this.

11. 11
Global Breast Cancer Therapeutics Market Analysis, 2022-2030
Medullary Carcinoma:
Medullary carcinoma accounts for 3-5% of all breast cancer types. While the tumour frequently appears on mam-
mography, it is not always felt as a bump. It can occasionally resemble a spongy breast tissue alteration.
There are other types that are less commonly seen-
Tubular Carcinoma:
Tubular carcinoma cells, which account for around 2% of all breast cancer diagnoses, have a recognisable tubular
form. A clump of cells that can feel more like a spongy patch of breast tissue than a lump is typically discovered by
a mammography. This particular kind of breast cancer typically affects women over the age of 50 and responds
favourably to hormone therapy.
Mucinous Carcinoma (Colloid):
A percentage of breast tumours between 1% and 2% is mucinous carcinomas. Mucus production and poorly
defined cells are the major characteristics that set them apart from one another. It typically has a good prognosis
as well.
Paget Disease of The Breast or Nipple:
A uncommon kind of cancer, breast Paget disease affects the skin of the nipple and frequently the areola, the
darker circle of skin surrounding the nipple. Most persons with Paget disease that is visible on the nipple also have
one or more tumours inside the same breast, which are often either invasive breast cancer or ductal carcinoma in
situ (1–3). The initial signs of Paget illness are usually misdiagnosed because they are easily mistaken for more wide-
spread skin disorders that affect the nipple. The prognosis for Paget disease, like all breast cancers, depends on a
number of variables, such as the existence or absence of invasive malignancy and whether or not it has spread to
neighbouring lymph nodes.

12. The treatment of breast cancer has made remarkable strides in recent years, offering a beacon of hope to those
affected by this pervasive disease. Breast cancer treatment is not a one-size-fits-all approach but rather a finely
tuned orchestra of therapies tailored to the specific type, stage, and individual characteristics of the cancer. From
surgical procedures designed to remove or reshape affected breast tissue to targeted therapies aimed at disrupt-
ing the molecular mechanisms of cancer growth, the landscape of breast cancer treatment is as diverse as it is
dynamic.
This comprehensive approach encompasses the traditional pillars of surgery, chemotherapy, and radiation
therapy, as well as the latest innovations in immunotherapy and precision medicine. With a better understanding
of these multifaceted treatment options, patients and healthcare providers alike can navigate the complex
journey towards defeating breast cancer with increased confidence and optimism.
12
What are the treatment options
for Breast Cancer?
Global Breast Cancer Therapeutics Market Analysis, 2022-2030
Drugs Approved to Prevent Breast Cancer
▪ Evista (Raloxifene Hydrochloride)
▪ Raloxifene Hydrochloride
▪ Soltamox (Tamoxifen Citrate)
▪ Tamoxifen Citrate

13. 13
Global Breast Cancer Therapeutics Market Analysis, 2022-2030
▪ Abemaciclib
▪ Abraxane (Paclitaxel Albumin-stabilized
Nanoparticle Formulation)
▪ Ado-Trastuzumab Emtansine
▪ Afinitor (Everolimus)
▪ Afinitor Disperz (Everolimus)
▪ Alpelisib
▪ Anastrozole
▪ Aredia (Pamidronate Disodium)
▪ Arimidex (Anastrozole)
▪ Aromasin (Exemestane)
▪ Capecitabine
▪ Cyclophosphamide
▪ Docetaxel
▪ Doxorubicin Hydrochloride
▪ Elacestrant Dihydrochloride
▪ Ellence (Epirubicin Hydrochloride)
▪ Enhertu (Fam-Trastuzumab Deruxtecan-nx-
ki)
▪ Epirubicin Hydrochloride
▪ Eribulin Mesylate
▪ Everolimus
▪ Exemestane
▪ 5-FU (Fluorouracil Injection)
▪ Fam-Trastuzumab Deruxtecan-nxki
▪ Fareston (Toremifene)
▪ Faslodex (Fulvestrant)
▪ Femara (Letrozole)
▪ Fluorouracil Injection
▪ Fulvestrant
▪ Gemcitabine Hydrochloride
▪ Gemzar (Gemcitabine Hydrochloride)
▪ Goserelin Acetate
▪ Halaven (Eribulin Mesylate)
▪ Herceptin Hylecta (Trastuzumab and
Hyaluronidase-oysk)
▪ Herceptin (Trastuzumab)
▪ Ibrance (Palbociclib)
▪ Infugem (Gemcitabine Hydrochloride)
▪ Ixabepilone
▪ Ixempra (Ixabepilone)
▪ Kadcyla (Ado-Trastuzumab Emtansine)
▪ Keytruda (Pembrolizumab)
▪ Kisqali (Ribociclib)
▪ Lapatinib Ditosylate
▪ Letrozole
▪ Lynparza (Olaparib)
▪ Margenza (Margetuximab-cmkb)
▪ Margetuximab-cmkb
▪ Megestrol Acetate
▪ Methotrexate Sodium
▪ Neratinib Maleate
▪ Nerlynx (Neratinib Maleate)
▪ Olaparib
▪ Orserdu (Elacestrant Dihydrochloride)
▪ Paclitaxel
▪ Paclitaxel Albumin-stabilized Nanoparticle
Formulation
▪ Palbociclib
▪ Pamidronate Disodium
▪ Pembrolizumab
▪ Perjeta (Pertuzumab)
▪ Pertuzumab
▪ Pertuzumab, Trastuzumab, and Hyaluroni-
dase-zzxf
▪ Phesgo (Pertuzumab, Trastuzumab, and
Hyaluronidase-zzxf)
▪ Piqray (Alpelisib)
▪ Ribociclib
▪ Sacituzumab Govitecan-hziy
▪ Soltamox (Tamoxifen Citrate)
▪ Talazoparib Tosylate
▪ Talzenna (Talazoparib Tosylate)
▪ Tamoxifen Citrate
▪ Taxotere (Docetaxel)
▪ Tecentriq (Atezolizumab)
▪ Tepadina (Thiotepa)
▪ Thiotepa
▪ Toremifene
▪ Trastuzumab
▪ Trastuzumab and Hyaluronidase-oysk
▪ Trexall (Methotrexate Sodium)
▪ Trodelvy (Sacituzumab Govitecan-hziy)
▪ Tucatinib
▪ Tukysa (Tucatinib)
▪ Tykerb (Lapatinib Ditosylate)
▪ Verzenio (Abemaciclib)
▪ Vinblastine Sulfate
▪ Xeloda (Capecitabine)
▪ Zoladex (Goserelin Acetate)
Drugs Approved to Treat Breast Cancer

14. Drug Combinations Used in Breast Cancer
▪ AC
▪ AC-T
▪ CAF
▪ CMF
▪ FEC
▪ TAC
14
Global Breast Cancer Therapeutics Market Analysis, 2022-2030
▪ Hormone therapy: This type of therapy is used for hormone receptor-positive breast cancers and includes
drugs that block the effects of estrogen on the cancer cells. Examples of hormone therapy drugs include tamox-
ifen, aromatase inhibitors (such as letrozole, anastrozole, and exemestane), and fulvestrant.
▪ Chemotherapy: Chemotherapy is a systemic treatment that can be used to treat various types and stages of
breast cancer. Examples of chemotherapy drugs used to treat breast cancer include taxanes (such as paclitaxel
and docetaxel), anthracyclines (such as doxorubicin and epirubicin), and cyclophosphamide.
▪ Targeted therapy: Targeted therapy drugs are designed to attack specific proteins or genes in cancer cells.
Examples of targeted therapy drugs used to treat breast cancer include trastuzumab, pertuzumab, lapatinib,
neratinib, and everolimus.
▪ Immunotherapy: Immunotherapy drugs work by stimulating the body's immune system to recognize and
attack cancer cells. For breast cancer, the immunotherapy drug atezolizumab is sometimes used in combina-
tion with chemotherapy for triple-negative breast cancer that is PD-L1 positive.
▪ PARP inhibitors: PARP inhibitors are a type of targeted therapy drug that work by blocking an enzyme involved
in DNA repair. These drugs are used to treat BRCA-mutated breast cancer and include olaparib, talazoparib,
and rucaparib.
▪ Bisphosphonates and denosumab: These drugs are used to help prevent bone loss and reduce the risk of
bone metastases in breast cancer patients. Examples of bisphosphonates include zoledronic acid and pamid-
ronate, while denosumab is a monoclonal antibody.
Below is a summary of some of the drugs commonly used to
treat breast cancer:

15. How big is the market for breast
cancer treatments, what
are the key trends?
15
Global Breast Cancer Therapeutics Market Analysis, 2022-2030
Breast Cancer Therapeutics
Market Size, By Region
(in $ Bn)
0.728
0.273
0.819
9.1
3.822
3.458
The data presented is tentative subject to change in the final report.
APAC
Europe
Middle East
Africa
Latin America
North America
Market Size and Key Findings

16. 16
Global Breast Cancer Therapeutics Market Analysis, 2022-2030
Regional Analysis
The Global Breast Cancer Therapeutics Market is categorized into five regions based on geography: North America,
Europe, Asia Pacific, Latin America, and the Middle East Africa. North America accounted for the largest share of
the global breast cancer drugs market in 2022 and is expected to remain dominant during the forecast period. This
growth can be attributed to the presence of well-established corporations in the area, leading to the introduction
of new treatments. Other contributing factors include the high incidence of breast cancer, a rising number of RD
clinical trials for breast cancer therapies, and increasing acceptance of cutting-edge medicines.
For instance, the American Cancer Society predicted that there would be about 276,480 new cases of invasive
breast cancer in women in the United States in 2020.
Due to the rising incidence of breast cancer and increased use of cutting-edge therapies in the region, Europe is
anticipated to be the second-most prominent region throughout the projection period. For instance, female breast
cancer is the most prevalent cancer diagnosed in Europe, according to figures provided by the Joint Research
Center (JRC) of the European Union. In the EU-27, it was predicted that more than 355,000 women would receive a
breast cancer diagnosis in 2020.
The region with the biggest growth is expected to be Asia Pacific, which will benefit from rising patient populations,
advanced medicine demand, and considerable increases in healthcare spending. For instance, F. Hoffmann-La
Roche Ltd. announced the arrival of atezolizumab, an immunotherapy medicine, in India in April 2020 for the treat-
ment of metastatic triple-negative breast cancer (TNBC).
In 2019, the Middle East and Africa's and Latin America's emerging markets contributed a considerably smaller
contribution. But because of the increased presence of well-known firms in the regions, rising healthcare costs,
soaring patient population, and high demand for sophisticated therapies, they are predicted to rise significantly
over the course of the projection year.

17. Breast Cancer Therapeutics Market Size, By Countries (in $ Bn)
Country 2022 CAGR 2030F
US
China
Canada
Japan
Germany
France
UK
Brazil
Italy
Spain
India
Saudi Arabia
South Korea
Australia
Turkey
UAE
Egypt
Hong Kong
Russia
Mexico
South Africa
Indonesia
Poland
Vietnam
Austria
Kuwait
Qatar
Sweden
Portugal
Romania
764.4
146.3
145.6
113.1
66.6
50.1
47.3
45.5
43.7
35.1
33.1
30.9
26.6
21.8
14.6
9.1
5.1
2.9
29.7
27.3
11.8
10.9
10.6
9.1
7.3
7.3
7.3
6.6
5.5
5.3
10.9%
14.4%
12.9%
13.4%
11.1%
11.9%
10.9%
13.9%
12.4%
11.9%
15.9%
14.4%
13.9%
14.4%
13.4%
13.9%
14.4%
13.9%
--
--
--
--
--
--
--
--
--
--
--
--
1748.9
429.2
384.3
309.4
154.6
123.0
108.3
128.9
111.3
86.4
107.8
90.8
75.3
64.1
39.8
25.8
14.9
8.3
--
--
--
--
--
--
--
--
--
--
--
--
17
Global Breast Cancer Therapeutics Market Analysis, 2022-2030

18. Netherlands
Philippines
Finland
Algeria
Malaysia
Morocco
Singapore
Nigeria
Thailand
New Zealand
Ireland
Norway
Denmark
Belgium
Ukraine
Bulgaria
Venezuela
Senegal
Switzerland
Lebanon
Kenya
Libya
Tanzania
Argentina
Ecuador
4.7
4.0
3.8
3.6
2.9
2.4
2.2
1.6
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
For Country Specific Breast Cancer Therapeutics Report
18
Global Breast Cancer Therapeutics Market Analysis, 2022-2030
Click here

19. Estimated age-standardized incidence rates (World) in 2020,
breast, all ages
≥ 69.2
53.0-69.2
41.1-53.0
30.3-41.1
30.3
Not applicable
No data
ASR (World) per 100 00
≥ 19.4
16.6 - 19.4
13.8 - 16.6
11.5 - 13.8
11.5
Not applicable
No data
ASR (World) per 100 00
Estimated age-standardized mortality rates (World) in 2020,
breast, all ages
19
Global Breast Cancer Therapeutics Market Analysis, 2022-2030

20. What are the key drivers of the Global Breast Cancer
Therapeutics Market?
What are the key restraints of the Global Breast Cancer
Therapeutics Market?
The global breast cancer therapeutics market is driven by several factors, including:
Increasing incidence of breast cancer: The incidence of breast cancer is on the rise globally, with an increasing
number of women being diagnosed with the disease each year. This has resulted in a growing demand for effective
treatments for breast cancer, which is driving the growth of the breast cancer therapeutics market.
Development of new and innovative drugs: There has been significant investment in research and development
to develop new and innovative drugs for the treatment of breast cancer. These new drugs have been shown to be
more effective and less toxic than traditional chemotherapy, and they are driving the growth of the breast cancer
therapeutics market.
Growing demand for personalized medicine: Personalized medicine is becoming increasingly important in the
treatment of breast cancer. This involves tailoring treatments to the specific genetic makeup of the patient, which
can result in more effective treatments and fewer side effects. The growing demand for personalized medicine is
driving the growth of the breast cancer therapeutics market.
Increasing healthcare expenditure: Healthcare expenditure is increasing globally, and this is leading to increased
investment in the development and distribution of breast cancer therapeutics. This is driving the growth of the
breast cancer therapeutics market.
Awareness and education initiatives: There are many initiatives and campaigns aimed at raising awareness
about breast cancer and the importance of early detection and treatment. These initiatives are driving the demand
for breast cancer therapeutics, as more women are being diagnosed and treated for the disease.
Market Dynamics
While the global breast cancer therapeutics market is expected to grow at a significant pace, there are also several
key restraints that could potentially slow down the growth of the market, including:
High cost of treatments: The cost of breast cancer treatments can be very high, which can be a significant barrier
to access for many patients, particularly in low- and middle-income countries. This could limit the growth of the
breast cancer therapeutics market in these regions.
Stringent regulatory requirements: The development and approval of new drugs for the treatment of breast
cancer is a lengthy and expensive process, with stringent regulatory requirements in place to ensure safety and
efficacy. This can slow down the development and approval of new treatments, which could limit the growth of the
market.
Side effects of treatments: Breast cancer treatments can have significant side effects, including nausea, fatigue,
hair loss, and cognitive impairment. This can limit the use of these treatments, particularly in older or more frail
patients, and could impact the growth of the market.
Alternative treatment options: Some patients may choose to explore alternative or complementary therapies for
the treatment of breast cancer, which could limit the growth of the breast cancer therapeutics market.
Lack of awareness and access: Despite growing awareness about breast cancer, there are still many regions
where women have limited access to healthcare and screening services. This could limit the growth of the breast
cancer therapeutics market, as patients may not be diagnosed and treated in a timely manner.
20
Global Breast Cancer Therapeutics Market Analysis, 2022-2030

21. Global Breast Cancer Therapeutics Market Analysis, 2022-2030
Which are the major players in the Global Breast Cancer
Therapeutics Market?
The global breast cancer therapeutics market is highly competitive, with several key players competing for market
share. Some of the key players in the market include:
Other key players in the global breast cancer therapeutics market include Sanofi, Merck, Celgene Corporation,
and Johnson Johnson. These companies invest heavily in research and development to develop new treatments
for breast cancer, and they also work to improve patient access to breast cancer treatments by expanding their
distribution networks and working with healthcare providers to improve diagnosis and treatment.
Competitive Landscape
21
Global Breast Cancer Therapeutics Market Analysis, 2022-2030
AstraZeneca is a British-Swedish multinational pharmaceutical company that develops and
manufactures a range of drugs for the treatment of breast cancer, including hormone
therapies, targeted therapies, and chemotherapy drugs.
Roche is a Swiss multinational pharmaceutical company that develops and manufactures a
range of drugs for the treatment of breast cancer, including targeted therapies and chemo-
therapy drugs.
Pfizer is an American multinational pharmaceutical company that develops and manufac-
tures a range of drugs for the treatment of breast cancer, including hormone therapies and
chemotherapy drugs.
Novartis is a Swiss multinational pharmaceutical company that develops and manufactures
a range of drugs for the treatment of breast cancer, including hormone therapies, targeted
therapies, and chemotherapy drugs.
Eli Lilly is an American multinational pharmaceutical company that develops and manufac-
tures a range of drugs for the treatment of breast cancer, including targeted therapies and
chemotherapy drugs.

22. 22
Global Breast Cancer Therapeutics Market Analysis, 2022-2030
How do breast cancer treatment markets,
healthcare policies, reimbursement scenarios
vary around the world?
Healthcare Policy and Regulatory Landscape
The healthcare policy and regulatory landscape for breast cancer therapeutics varies across different regions and
countries. However, there are some common themes and initiatives that are aimed at improving access to breast
cancer treatment and care.
In the US, the Food and Drug Administration (FDA) is responsible for the regulation of drugs and therapies for
the treatment of breast cancer. The FDA has established a comprehensive regulatory framework for the develop-
ment, testing, and approval of new treatments for breast cancer. The agency has also implemented various initia-
tives aimed at expediting the development and approval of new drugs for serious or life-threatening diseases,
including breast cancer. These initiatives are aimed at increasing patient access to new and innovative therapies.
In Europe, the European Medicines Agency (EMA) is responsible for the regulation of drugs and therapies for the
treatment of breast cancer. The EMA has established a comprehensive regulatory framework that is aimed at
ensuring the safety and efficacy of new treatments for breast cancer. The agency has also implemented various
initiatives aimed at improving patient access to new and innovative therapies.
In addition to regulatory agencies, there are also various healthcare policy initiatives and organizations that are
working to improve access to breast cancer treatment and care. For example, the World Health Organization
(WHO) has established a global breast cancer initiative aimed at improving access to screening, diagnosis, and
treatment for breast cancer. The initiative is focused on improving awareness about breast cancer, increasing
access to screening and diagnosis, and improving access to quality treatment and care.
Overall, the healthcare policy and regulatory landscape for breast cancer therapeutics is complex and constantly
evolving. However, there is a growing focus on improving patient access to innovative and effective treatments, and
on improving awareness and education about breast cancer.

23. Reimbursement Scenario
Reimbursement for breast cancer therapeutics varies depending on the country and the specific treatment
involved. Generally, breast cancer therapeutics reimbursement is typically provided through a combination of
public and private health insurance programs.
In the US, reimbursement for breast cancer therapeutics is typically provided through private health insurance
plans or public insurance programs such as Medicare and Medicaid. Private health insurance plans typically cover
a portion of the cost of breast cancer treatments, but patients may still be responsible for co-payments, deduct-
ibles, and other out-of-pocket expenses. Medicare and Medicaid also cover a portion of the cost of breast cancer
treatments, but coverage varies depending on the specific treatment and the patient's eligibility.
In Europe, reimbursement for breast cancer therapeutics is typically provided through national healthcare systems.
Coverage and reimbursement policies vary depending on the country, but most national healthcare systems
provide coverage for breast cancer treatments. In some countries, patients may be responsible for co-payments or
other out-of-pocket expenses.
In other regions, such as Asia and Latin America, reimbursement for breast cancer therapeutics may be provided
through a combination of public and private health insurance programs. However, access to healthcare and reim-
bursement for breast cancer treatments may be limited in some regions due to factors such as cost, lack of infra-
structure, and limited healthcare resources.
Overall, reimbursement for breast cancer therapeutics is an important factor in patient access to care. Govern-
ments, regulatory agencies, and healthcare organizations are working to improve patient access to effective and
affordable breast cancer treatments, including by implementing reimbursement policies that support the use of
these treatments.
23
Global Breast Cancer Therapeutics Market Analysis, 2022-2030

24. 24
Global Breast Cancer Therapeutics Market Analysis, 2022-2030
WHO Launches New Roadmap on Breast Cancer
In February 2023, the World Health Organization (WHO) launched a
new Global Breast Cancer Initiative Framework that serves as a road
map for achieving the goals of 2.5 Mn lives save from breast cancer by
2040. The new Framework advises nations to put the three health
promotion pillars of early detection, prompt diagnosis, and thorough
management of breast cancer into practise in order to meet the
targets.
In order to develop resource-appropriate, country-specific health systems for the delivery of breast cancer care in
low- and middle-income countries, a recently published framework makes use of tried-and-true techniques. With
precise critical performance metrics, it specifies three action pillars:
▪ Advising nations to prioritise breast cancer early-detection initiatives so that at least 60% of breast cancer cases
are identified and treated in the early stages
▪ Breast cancer outcomes can be improved by receiving a diagnosis within 60 days of the initial appearance. After
the initial presentation, treatment should begin within three months
▪ Managing breast cancer should ensure that at least 80% of patients finish the suggested course of treatment
What are the latest trends and innovations in
the global breast cancer market?

25. AI in Breast Cancer
Artificial intelligence (AI) technology has been developed by engineers at the University of
Waterloo to determine whether chemotherapy before surgery would be beneficial for people
with breast cancer.
Choosing the best course of action for a specific breast cancer patient is currently highly
challenging, and it is critical to prevent unwanted side effects from being caused by treat-
ments that are unlikely to actually benefit the patient.
The open-source Cancer-Net initiative's new AI system could help unsuitable candidates avoid the harmful side
effects of chemotherapy and improve surgical outcomes for those who are qualified. It is lead by Dr. Alexander
Wong.
Conclusion
The breast cancer market has seen significant growth over the past few years, driven by rising awareness of the
disease, improved screening and diagnostic technologies, and advancements in treatment options. Additionally, the
increasing incidence of breast cancer and the growing aging population have also contributed to the growth of the
breast cancer market.
In terms of regional markets, North America and Europe are currently the largest markets for breast cancer prod-
ucts and services. However, emerging markets such as Asia-Pacific and Latin America are expected to grow rapidly
in the coming years due to improving healthcare infrastructure, rising disposable incomes, and increasing aware-
ness of breast cancer.
Due to the limited research and development in these particular fields, there are few treatment options and medi-
cations available for rare kinds of breast cancer. Patients and healthcare experts who are attempting to manage
and treat these forms of breast cancer may find this to be a substantial obstacle.
Inflammatory breast cancer, triple-negative breast cancer, and HER2-positive breast cancer are a few uncommon
types of the breast cancer. It is crucial to have access to appropriate treatments because some forms of breast
cancer can be more aggressive and challenging to treat than more typical forms.
Overall, the global breast cancer market is expected to continue to grow in the coming years, driven by factors such
as rising incidence rates, increasing awareness and screening, and advancements in treatment options. However,
the high cost of cancer treatments and the lack of access to quality healthcare in certain regions remain major
challenges in the breast cancer market.
25
Global Breast Cancer Therapeutics Market Analysis, 2022-2030

26. ABOUT
INSIGHTS10
Insights10 is a healthcare-focused market research firm founded with an aim of being an insights-driven company
in the data-driven world and delivering actionable insights that can drive decisions and strategy-making processes
for our clients.
It is a market research firm that provides syndicated and customized research reports in healthcare and allied
industries such as Pharmaceuticals, Diseases/Therapies, Medical Devices, Digital Health, Healthcare Services, OTC
and Nutraceuticals, etc.
Our qualitative, acute, and result-oriented market research reports provide a comprehensive understanding of
the business scenario and the latest trends related to the life sciences market.
Whether you are looking to expand into new areas, develop new products, or take advantage of new opportuni-
ties we have reports to help you accelerate and improve your plans by identifying unique growth prospects.
www.insights10.com
https://www.cancer.gov/about-cancer/treatment/drugs/breast
https://theprint.in/science/study-artificial-intelligence-detect-effectiveness-of-breast-cancer-chemotherapy/
1359920/
https://www.who.int/news/item/03-02-2023-who-launches-new-roadmap-on-breast-cancer#:~:text=The%20
World%20Health%20Organization%20(WHO,from%20breast%20cancer%20by%202040
References
26
Global Breast Cancer Therapeutics Market Analysis, 2022-2030

27. Insights, not just research
Author
Shivam Zalke
Consultant, Insights10
CONTACT US
821, Sun Avenue One Manekbag,
Ambawadi, Amdedabad, India
info@insights10.com
www.insights10.com
© 2023 Insights10 | All rights reserved.